Xvivo Perfusion AB (publ)

OM:XVIVO Voorraadrapport

Marktkapitalisatie: SEK 15.7b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Xvivo Perfusion Beheer

Beheer criteriumcontroles 3/4

De CEO Xvivo Perfusion's is Christoffer Rosenblad, benoemd in Jan2022, heeft een ambtstermijn van 2.75 jaar. bezit rechtstreeks 0.18% van de aandelen van het bedrijf, ter waarde SEK 27.98M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.3 jaar en 4 jaar.

Belangrijke informatie

Christoffer Rosenblad

Algemeen directeur

SEK 5.0m

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEO2.8yrs
Eigendom CEO0.2%
Management gemiddelde ambtstermijn2.3yrs
Gemiddelde ambtstermijn bestuur4yrs

Recente managementupdates

Recent updates

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 40% Undervaluation?

Aug 03
Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 40% Undervaluation?

Xvivo Perfusion AB (publ) (STO:XVIVO) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

Apr 25
Xvivo Perfusion AB (publ) (STO:XVIVO) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

There Are Reasons To Feel Uneasy About Xvivo Perfusion's (STO:XVIVO) Returns On Capital

Apr 11
There Are Reasons To Feel Uneasy About Xvivo Perfusion's (STO:XVIVO) Returns On Capital

Need To Know: Analysts Just Made A Substantial Cut To Their Xvivo Perfusion AB (publ) (STO:XVIVO) Estimates

Feb 05
Need To Know: Analysts Just Made A Substantial Cut To Their Xvivo Perfusion AB (publ) (STO:XVIVO) Estimates

We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings

Feb 01
We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings

Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jan 28
Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Returns On Capital At Xvivo Perfusion (STO:XVIVO) Have Stalled

Aug 24
Returns On Capital At Xvivo Perfusion (STO:XVIVO) Have Stalled

Why Xvivo Perfusion AB (publ) (STO:XVIVO) Could Be Worth Watching

Jul 17
Why Xvivo Perfusion AB (publ) (STO:XVIVO) Could Be Worth Watching

Do Xvivo Perfusion's (STO:XVIVO) Earnings Warrant Your Attention?

Jun 16
Do Xvivo Perfusion's (STO:XVIVO) Earnings Warrant Your Attention?

Xvivo Perfusion (STO:XVIVO) May Have Issues Allocating Its Capital

Apr 19
Xvivo Perfusion (STO:XVIVO) May Have Issues Allocating Its Capital

Are Investors Undervaluing Xvivo Perfusion AB (publ) (STO:XVIVO) By 21%?

Mar 23
Are Investors Undervaluing Xvivo Perfusion AB (publ) (STO:XVIVO) By 21%?

With EPS Growth And More, Xvivo Perfusion (STO:XVIVO) Makes An Interesting Case

Mar 07
With EPS Growth And More, Xvivo Perfusion (STO:XVIVO) Makes An Interesting Case

When Should You Buy Xvivo Perfusion AB (publ) (STO:XVIVO)?

Feb 13
When Should You Buy Xvivo Perfusion AB (publ) (STO:XVIVO)?

Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

Dec 14
Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 35% Undervaluation?

Nov 17
Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 35% Undervaluation?

Xvivo Perfusion (STO:XVIVO) Might Be Having Difficulty Using Its Capital Effectively

Aug 20
Xvivo Perfusion (STO:XVIVO) Might Be Having Difficulty Using Its Capital Effectively

Statutory Profit Doesn't Reflect How Good Xvivo Perfusion's (STO:XVIVO) Earnings Are

Jul 21
Statutory Profit Doesn't Reflect How Good Xvivo Perfusion's (STO:XVIVO) Earnings Are

Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

Mar 30
Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

At kr258, Is Xvivo Perfusion AB (publ) (STO:XVIVO) Worth Looking At Closely?

Feb 18
At kr258, Is Xvivo Perfusion AB (publ) (STO:XVIVO) Worth Looking At Closely?

A Look At The Fair Value Of Xvivo Perfusion AB (publ) (STO:XVIVO)

Jan 30
A Look At The Fair Value Of Xvivo Perfusion AB (publ) (STO:XVIVO)

CEO

Christoffer Rosenblad (49 yo)

2.8yrs

Tenure

SEK 5,031,000

Compensatie

Mr. Christoffer Rosenblad serves as Chief Executive Officer at Xvivo Perfusion AB (publ) since November 30, 2022. He served as Deputy Chief Executive Officer and Global Business Development & Service Direc...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Christoffer Rosenblad
Chief Executive Officer2.8yrsSEK 5.03m0.18%
SEK 27.7m
Kristoffer Nordstrom
Chief Financial Officer3.9yrsgeen gegevens0.0085%
SEK 1.3m
Lena Hagman
Chief Operating Officer1.8yrsgeen gegevens0.0063%
SEK 997.1k
Johan Holmstrom
Senior Vice President of Commercial EMEAless than a yeargeen gegevens0.012%
SEK 1.8m
Ylva Vihoj
Global Human Resources Director1.8yrsgeen gegevensgeen gegevens
Magnus Nilsson
Senior Advisor4.3yrsSEK 1.62mgeen gegevens
Andreas Wallinder
Chief Medical Officer4.1yrsgeen gegevens0.011%
SEK 1.7m
Mark Reade
Senior Vice President of North Americaless than a yeargeen gegevensgeen gegevens

2.3yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van XVIVO wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.3 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Gosta Johannesson
Chairman of the Board11.8yrsSEK 440.00k0.015%
SEK 2.3m
Lars Henriksson
Independent Director4yrsgeen gegevens0.0076%
SEK 1.2m
Erik Stromqvist
Independent Director1.5yrsgeen gegevens0.18%
SEK 27.7m
Camilla Oberg
Independent Director8.4yrsSEK 130.00k0.0034%
SEK 537.0k
Lena Hoglund
Independent Director4yrsgeen gegevens0.0041%
SEK 648.5k
Goran Dellgren
Independent Director2.5yrsgeen gegevensgeen gegevens

4.0yrs

Gemiddelde duur

63.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van XVIVO wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).